GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Total Operating Expense

EyePoint Pharmaceuticals (STU:PV3B) Total Operating Expense

: €108.02 Mil (TTM As of Dec. 2023)
View and export this data going back to 2009. Start your Free Trial

EyePoint Pharmaceuticals's Total Operating Expense for the three months ended in Dec. 2023 was €26.95 Mil. EyePoint Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €108.02 Mil.

EyePoint Pharmaceuticals Total Operating Expense Historical Data

The historical data trend for EyePoint Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.99 54.17 74.37 105.74 106.79

EyePoint Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Operating Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.47 26.71 27.76 26.61 26.95

EyePoint Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €108.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Pharmaceuticals Total Operating Expense Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Total Operating Expense
Comparable Companies
RGNX BCRX KYTX SLNCF SPRY IMTX ETNB RLAY INVA VRDN OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
EYPT:USA
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
Website
https://www.eyepointpharma.com
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines